Ascendis Pharma A/S (NASDAQ:ASND) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report released on Monday morning, Benzinga reports. They currently have a $170.00 target price on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S’s FY2024 earnings at ($6.54) EPS.

A number of other research analysts have also recently issued reports on ASND. Jefferies Financial Group lifted their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a buy rating in a research report on Tuesday, August 13th. Stifel Nicolaus assumed coverage on Ascendis Pharma A/S in a report on Friday, May 31st. They issued a buy rating and a $200.00 price objective for the company. JPMorgan Chase & Co. lowered their price target on Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating on the stock in a report on Wednesday, September 4th. Citigroup reduced their price objective on Ascendis Pharma A/S from $193.00 to $178.00 and set a buy rating for the company in a research note on Wednesday, September 4th. Finally, Evercore ISI upgraded shares of Ascendis Pharma A/S to a strong-buy rating in a research report on Monday, August 26th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of $193.77.

Ascendis Pharma A/S Trading Up 1.6 %

Shares of NASDAQ:ASND opened at $148.88 on Monday. The company has a 50-day moving average price of $132.71 and a 200-day moving average price of $136.43. The company has a market cap of $8.67 billion, a price-to-earnings ratio of -15.22 and a beta of 0.63. Ascendis Pharma A/S has a 12 month low of $85.29 and a 12 month high of $161.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Private Ocean LLC acquired a new position in shares of Ascendis Pharma A/S in the 1st quarter valued at $36,000. GAMMA Investing LLC lifted its stake in Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 102 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after buying an additional 151 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the period. Finally, Bessemer Group Inc. grew its stake in shares of Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 332 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.